David Kerstein

2.8k citations
56 papers · 1.4k · 1 hit paper · h-index 17

Impact in

Papers in

David Kerstein

54 papers receiving 1.4k citations

David Kerstein's Hit Papers

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial 2017 · 430 citations
4300+3+6Years since publication100200300400

Peers

David Kerstein
Comparison fields: 5 of 62
  • Pulmonary and Respiratory Medicine 1.2k
  • Oncology 991
  • Genetics 173
  • Cancer Research 209
  • Hematology 91
Replace Zhongsheng Tong with:
Zhongsheng Tong China
Fábio Franke United States
Walter L. Vervenne Netherlands
Vladimir Vladimirov United States
V. A. Miller United States
Tindara Franchina Italy
Thanyanan Reungwetwattana Thailand
Oezlem Anak United States
Yuichi Sakamori Japan
Maja J. De Jonge Netherlands
David Kerstein relative to Zhongsheng Tong China Zhongsheng Tong's profile →
Citations per field
00.5×4.3×
Zhongsheng Tong · 1×
Citations per year

Countries citing papers authored by David Kerstein

Since Specialization
Citations

This map shows the geographic impact of David Kerstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Kerstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Kerstein more than expected).

Fields of papers citing papers by David Kerstein

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Kerstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Kerstein. The network helps show where David Kerstein may publish in the future.

Co-authors

The 25 scholars most cited alongside David Kerstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Kerstein Line = papers co-authored together David Kerstein links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase–Positive Non–Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial
Hit paper breakdown →
2017430
2 2016261
3 2018112
4 2019101
5 201548
6 201635
7 201628
8 202026
9 201825
10 201824
11 201323
12 201919
13 201818
14 201518
15 201817
16 201416
17 201616
18 202015
19 202014
20 201813

About David Kerstein

David Kerstein is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Hematology, Molecular Biology and Genetics, having authored 56 papers that have together received 1.4k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (47 papers), Lung Cancer Research Studies (23 papers), Colorectal Cancer Treatments and Studies (20 papers), Chronic Myeloid Leukemia Treatments (11 papers), Chronic Lymphocytic Leukemia Research (10 papers), Cancer Genomics and Diagnostics (8 papers), Gastrointestinal Tumor Research and Treatment (7 papers) and PI3K/AKT/mTOR signaling in cancer (7 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (1.2k citations), Oncology (991 citations), Genetics (173 citations), Cancer Research (209 citations) and Hematology (91 citations). David Kerstein has collaborated with scholars based in United States, Spain and South Korea. Frequent co-authors include Corey J. Langer, Scott Gettinger, D. Ross Camidge, Frank G. Haluska, Howard West, Marcello Tiseo, Rudolf M. Huber, Myung‐Ju Ahn, Maximilian J. Hochmair and William M. Reichmann. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Journal of Thoracic Oncology, Investigational New Drugs and CPT Pharmacometrics & Systems Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact